- R&D Day to be live video webcasted on Friday, June 21st at 10:00 AM ET - Norwood, MA, June 17, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or.
Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates.
Biotechnology
1d
5d
1m
6m
1y
Max
Corbus Pharmaceuticals Holdings Inc. News
12 Jun
Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profi
ACR CRISS score remains ≥ 0.95 (95%) at 21 months in systemic sclerosis open-label extension (OLE) studyCDASI activity score reaches -21.8 points at 16 months in dermatomyositis.
12 Jun
Corbus up 3% premarket on positive lenabasum data in rare autoimmune disorders
Corbus Pharmaceuticals (NASDAQ: CRBP ) perks up 3% premarket on light volume in response to longer term data on lenabasum in mid-stage studies in systemic sclerosis (SSc) and dermatomyositis (DM). The...
10 Jun
Robbins Arroyo LLP: Corbus Pharmaceuticals Holdings, Inc. (CRBP) Sued for Misleading Shareholders
Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) filed a class action complaint against the company for alleged...
29 May
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June
Norwood, MA, May 29, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating.
28 May
Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting
New data from ongoing Phase 2 open-label extension of lenabasum in systemic sclerosis and open-label extension data in dermatomyositis studies to be presentedPresentation.
24 May
Does Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Pay Compare Well With Peers?
Yuval Cohen became the CEO of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) in 2014. First, this article will...
The following slide deck was published by Corbus Pharmaceuticals Holdings, Inc. in conjunction with this Read more …
Here's what investors need to know about this company's synthetic cannabinoid.
15 May
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May
Norwood, MA, May 15, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating.
About Corbus Pharmaceuticals Holdings Inc.
The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
Corbus licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 novel compounds targeting the endocannabinoid system from Jenrin Discovery LLC. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist specifically designed to eliminate blood-brain barrier penetration and brain CB1 receptor occupancy that mediate the neuropsychiatric issues associated with first-generation CB1 inverse agonists. Potential indications for CRB-4001 include NASH, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis, among others. CRB-4001 is scheduled to enter a Phase 1 study in 2019 followed by a National Institutes of Health (NIH)-funded first-in-patient Phase 2 study.
Team
Barbara White
Chief Medical Officer
Alan Holmer
Chairman of the Board
Avery W. Catlin
Director
$ 7.77
1.30%
Open:
7.61
High:
7.92
Low:
7.56
Market cap:
441.518 M
Symbol:
CRBP
Contact info
Phone:
+1 617-963-0100
+1 617-415-7745
+1 833-475-8247
Address:
500 River Ridge Dr, Norwood, MA 02062, USA
Hours
Mon
8:30
-
17:30
Tue
8:30
-
17:30
Wed
8:30
-
17:30
Thu
8:30
-
17:30
Fri
8:30
-
17:30